MIMG 170
Cell and Gene Therapy
Grades
3.76
Average grade awarded in MIMG 170. Not a student rating: this is what the grades were.
In the A range
75%
of the 164 letter grades
D, F or W
0.6%
of every letter grade awarded, plus withdrawals
Taken pass/no pass
1%
1 of 1 student passed
The registrar's own records: 164 grades over 4 terms, Fall 2021 to Fall 2025. Every instructor is pooled here.
What is inside that record
No summer session is in that record.
The table below splits them, and term averages across those 4 terms ran 3.44 to 3.94.
Historical grades for all professors, across recorded terms. The course summary above includes all professors.
- A+ 33 · 20.1%
- A 83 · 50.6%
- A- 7 · 4.3%
- B+ 24 · 14.6%
- B 15 · 9.1%
- C+ 1 · 0.6%
- F 1 · 0.6%
- P 1 of 165
Percentages are of the 164 letter grades. Grey bars are non-letter outcomes: passes (P).
How the non-letter outcomes are counted
They are excluded from the GPA entirely rather than scored, because counting a P as a 4.0 would be a fabrication.
By instructor
| Instructor | Predicted GPA | Raw | n | Terms | A range | Workload | Summer Session C 2026 |
|---|---|---|---|---|---|---|---|
| PYLE, APRIL DAWN reviews ↗ | 3.76 | 3.76 | 164 | 4 | 75% | - | not teaching it |
Why Predicted is not the Raw average
“Predicted” is shrunk toward the course average, which is itself shrunk toward the department, so an instructor with a handful of students sits near the course mean rather than topping the list.
Grade records describe outcomes. For what a course is like to take, read student reviews written on dibs below or follow the separate external review link.
Workload and assignments
Work types reported in BruinWalk reviews of this course, across recorded instructors and terms. They may differ from this term's syllabus.
dibs has not read this course’s reviews, so it cannot say what kind of work it sets. That is dibs not having looked. It is not a course without papers or exams, and the reviews linked below are the answer until dibs catches up.
What comes first
dibs has not read a class page for MIMG 170 in any term it holds, so it cannot say what comes before it.
Counted in courses rather than quarters: dibs does not know which of them a department lets you take together.
From the registrar's catalog
Lecture, three and one half hours; discussion, one hour. Requisites: Chemistry 153A, Life Sciences 107. State-of-art study of stem cells and gene therapy, and approaches to treat congenital/genetic defects, diseases, or injuries in humans. Review of current knowledge of human stem cells and viral and non-viral gene delivery strategies, and how they can be safely evaluated in animal models of disease. Introduction to ethical and legal issues related to cell and gene therapy as well as how to translate therapies into practice including aspects of cell and gene therapy intellectual property, regulatory, and Food and Drug Administration considerations. Includes innovative mock company team pitches to venture capitalists to learn how to raise capital for their new inventions based on what they have learned. Letter grading.
Sections in Summer Session C 2026
From the people who took it
Student reviews
What taking MIMG 170 was like: the work, the teaching, and what students wish they’d known.
Your experience could be the first.
No student reviews are available to read on dibs for this course yet. Took it? Tell the next person what helped, what was hard, and how you spent your time.
Looking for more perspectives?
External reviews are separate and do not count toward the dibs rating.